vTv Therapeutics (VTVT) Q3 2025 earnings summary

Executive summary

• Focused on developing oral, small molecule drug candidates for diabetes and chronic diseases, with lead candidate cadisegliatin in Phase 3 for type 1 diabetes; first patient randomized in pivotal CATT1 trial in August 2025, with topline data expected in H2 2026.

• No product revenue to date; revenue derived from milestone and license payments.

• FDA clinical hold on cadisegliatin was lifted in March 2025; CATT1 trial duration shortened.

• $80M raised in August/September 2025 private placement to support ongoing operations and clinical development.

• Secured new U.S. patent for crystalline salt forms of cadisegliatin, extending exclusivity to 2041.

Financial highlights

• Net loss attributable to common shareholders was $8.7M ($1.08 per share) for Q3 2025 vs. $4.8M ($0.88 per share) in Q3 2024; $19.8M for nine months ended September 30, 2025 vs. $14.8M in 2024.

• No revenue in Q3 2025; $1.0M revenue in nine months ended September 30, 2024 from a milestone payment.

• Research and development expenses increased 117.7% year-over-year to $7.0M in Q3 2025, driven by higher spending on cadisegliatin and a $1.0M Novo Nordisk milestone accrual.

• G&A expenses increased to $3.7M in Q3 2025 from $3.3M in Q3 2024, mainly due to payroll and legal costs.

• Cash and cash equivalents were $98.5M as of September 30, 2025, up from $36.7M at December 31, 2024.

Outlook and guidance

• Expects continued significant R&D expenses as cadisegliatin and other candidates advance.

• Top-line data from the CATT1 trial anticipated in the second half of 2026; additional registrational studies planned for 2027.

• Evaluating further financing strategies, including equity investments and licensing/monetization of programs.

• Proceeds from private placement expected to fund ongoing clinical development.